Raphaël De Coninck will participate in a live debate on “Investment Arguments in Merger Control.”
For more information, click here.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...
